Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1 NP001 Study in the Treatment of ALS

Neuraltus Pharmaceuticals reported that successful completion of a Phase I study in a small cohort of ALS patients treated with NP001, a small molecule drug proposed to regulate macrophage activity. While the primary objectives were safety and tolerability, the study also gathered data to evaluate an unidentified candidate blood based biomarker to measure the drug’s engagement with its target.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail